Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC) Meeting Abstract
| Authors: | Grisham, R. N.; Vergote, I.; Banerjee, S. N.; Drill, E. N.; Fabbro, M.; Mirza, M. R.; Romero, I.; Coleman, R. L.; Oza, A. M.; Hilpert, F.; Moore, K. N.; Westermann, A. M.; Aghajanian, C.; Scambia, G.; Boyd, A. P.; Cantey-Kiser, J.; O'Malley, D. M.; Farley, J. H.; Colombo, N.; Monk, B. J. |
| Abstract Title: | Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120603122 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.5519 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 5519 -- Source: Wos |
